Abstract
Overview
Introduction
Biologics are forecast to be the fastest growing segment of the pharmaceutical
market out to 2010 (12.2% CAGR). However, biologics face the emergence of
bio-similars and increasing numbers of competitor products, both factors that
intensify the commercial need for next-generation biologics with superior
product characteristics. DME-a method for optimizing biologics-directly
addresses this need.
Scope
- Assessment of the DME total market opportunity using global sales
forecasts for all biologics, split by company and therapy area, spanning
2001-10
- Classification system for understanding DME technologies - decomposing the
process into diversification, selection and protein format steps
- Detailed company analysis of both AME and Maxygen in terms of corporate
history, internal pipeline, alliance networks and financial performance
- Analysis of how companies such as MorphoSys and CAT are using 'display
systems' to accelerate the DME process in drug discovery
Report Highlights
Alliance network maps revealing which pharmaceutical players are accessing DME
through product technology collaborations with AME and Maxygen - including an
analysis of how Eli Lilly's 2004 acquisition of AME redefined the DME
competitive landscape.
Case study of how MedImmune applied DME to its marketed anti-RSV monoclonal
antibody Synagis to create the next-generation product Numax, which is
forecast to produce global sales in excess of $1bn by 2010.
Review of the major DME technologies which are in use with a consideration of
their relative strengths and weaknesses and suitability for different
commercial applications.
Reasons to Purchase
- Learn how DME opens up a route to generating highly optimized versions of
currently marketed biologics and vaccines
- Understand how DME can be applied in the discovery and development process
to enhance the binding affinity and stability of biologic lead candidates
- Identify the key holders of DME technology, how to gain access to this
powerful method and which techniques are best suited to which biomolecule types
| 
View Cart
